The Results Are In
The First Ever Clinical Study of VigRX Plus® With Real Men Is Now Complete And The Results Are Outstanding. In Just 84 Days, Study Participants Saw A:
- 58.97% INCREASE In The Ability To Penetrate Their Partner
- 71.43% INCREASE In Sexual And Intercourse Satisfaction
- 47% INCREASE In Overall Sex Drive And Desire
- 62.82 INCREASE In The Ability to Maintain an Erection
- 22.49% INCREASE In Frequency and Quality of Orgasms
- 61% INCREASE In Overall Sexual Desire
We knew it was good, but we didn’t know it was that good!
The Results shown were from a triple-blind placebo controlled, randomized Clinical Study by Vedic Lifesciences Pvt. LTD.
For the last ten years, we’ve been getting feedback directly from our customers about VigRX Plus®, so we already knew that it was extremely potent.
But we have to admit, even we were a touch surprised when we received the results of our 84-day clinical study completed by Vedic Lifesciences Pvt. Ltd.
If you like, you’re welcome to read the 56-page clinical study report that we received directly from Vedic Lifesciences.
However, we know you’re busy, so we’ve summarized a few of the most notable results from study participants below for your convenience:
The clinical study was performed by Vedic Lifesciences Pvt. Ltd.
The clinical study was performed by Vedic Lifesciences Pvt. Ltd.
It was a triple-blind study, which means nobody involved in evaluating the results, such as the doctors and researchers knew whether the participants were taking VigRX Plus® or the placebo. The trial ran for 84 days, with assessment visits taking place on Day 28, Day 56, and Day 84.
- Erection Frequency
- Erection Firmness
- Frequency of Partner Penetration
- Frequency of Maintaining An Erection After Penetration
- Ability To Maintain An Erection To Completion Of Intercourse
- Confidence In Achieving And Maintaining An Erection
The results were assessed using the International Index of Erectile Function (IIEF). This system of assessment is well respected throughout the international community. It has demonstrated consistent treatment responsiveness in studies in the U.S., Europe, and Asia. It measures:
Patient and partner satisfaction was measured using the internationally recognized Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire.
Prior to the start of the study, the protocols and amendments were submitted to and formally approved by the Independent Institutional Ethics Committee (IEC).
The 75 men who participated in the study were between the ages of 25 and 50, in monogamous, heterosexual relationships.
They agreed to take the recommended dose of VigRX Plus®, which is two capsules, twice per day with meals for 12 weeks.
Out of 108 applicants screened, 78 were recruited for participation in the trial, and 75 completed the trial.
No participants had major psychiatric disorders, a history of heart conditions, diabetes, spinal cord injuries, deformities of the penis, HIV/Aids, or sexually transmitted diseases. None were alcoholics, used medications known to causes sexual dysfunction, had liver or renal dysfunction, erection issues caused by low testosterone, or had female partners who were pregnant.
62.82% increase in ability to maintain erection During penetration
After 84 days of supplementation with VigRX Plus®, guys who participated in the trial saw a 62.82% increase in their ability to keep their erection thick, full, and firm during penetration of their partner.
This was as compared to the placebo group, see the chart.
58.97% increase in ability to penetrate partner
During this study, both the patient AND their sexual partners were questioned using the EDITS scale. Their sexual satisfaction was measured and compared – VigRX Plus® vs. the placebo.
One particularly interesting result: Female partners of patients taking VigRX Plus® reported a 58.97% increase in their partner’s ability to penetrate them with dramatic improvements in their overall satisfaction.
Meanwhile, those partners of patients taking the placebo reported a DECREASE in penetration during this same period.
See the chart below:
22.49% increase in quantity of orgasms
Compared to the placebo group, the men taking VigRX Plus® reported, over the 84 day test period, a 22.49% increase in the total number of orgasms they had.
Last we checked, more orgasms definitely equated to BETTER overall sexual satisfaction.
47% Increase In Sex Drive And Desire
One of the reasons VigRX Plus® was evaluated to be potentially superior to prescription erection medications is because it has been shown to measurably increase the desire for sex.
Prescription meds just affect your erections. They don’t impact your sex drive.
Yet sex drive and erection quality are LINKED.
Because VigRX Plus® has been shown to increase the desire for sex by 47%, as well as increase erection quality and frequency, it does something that prescription meds simply were not designed to do.
71.43% Increase in sexual and intercourse satisfaction
Men who took VigRX Plus® for the trial period also reported a 71.43% improvement in their sexual and intercourse satisfaction.
This was compared to the only 12% improvement reported by those who took the placebo.
That means guys who took VigRX Plus® were almost six times more sexually satisfied during the 84-day trial than those who took the placebo.
61% Increase In Overall Sexual Satisfaction
Finally, when all of the results were in, after 84 days the patients taking VigRX Plus® reported a 61% increase in their overall sexual satisfaction.
In contrast, the placebo group reported a DECREASE in overall satisfaction.
Don’t forget: this was a triple-blind study, which means the doctors, the researchers, and the patients all had NO IDEA whether they’d taken the placebo or VigRX Plus®.
This completely eliminates any bias in the results.
Erection Quality Scores Compared Over 12 Weeks:
As you can see, over the 12 week trial period, VigRX Plus® produced measurable increases in erection quality scores when compared to the placebo.
Study Participants Answered The Question:
“Would You Continue Taking VigRX Plus® Or The Placebo, Yes or No?”
VigRX Plus® Study References
National Institutes of Health Consensus Development Panel on impotence: JAMA 1993, 270(1):83–90
Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, Wang T: for the GSSAB Investigators’ Group: Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005, 17:39–57.
Aytac A, McKinlay JB, Krane RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. Br J Urol Int 1999, 84:450–456
Shamloul R: Natural aphrodisiacs. J Sex Med 2010, 7:39–49
Tamler R, Mechanick JI: Dietary supplements and nutraceuticals in the management of andrologic disorders. Endocrinol Metab Clin North Am 2007, 36(2):533–552.
McKay D: Nutrients and botanicals for erectile dysfunction: examining the evidence. Altern Med Rev 2004, 9(1):4–16
Dietary Supplement Health and Education Act of 1994 (DSHEA).
Villafranco JE, Bond K: Dietary supplement labeling and advertising claims: are clinical studies on the full product required? Food Drug Law J 2009, 64(1):43–67.
Glisson JK, Walker LA: How physicians should evaluate dietary supplements. Am J Med 2010, 123(7):577–582
Fleshner N, Harvey M, Adomat H, Wood C, Eberding A, Hersey K, Guns E: Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. J Urol 2005, 174(2):636–641.
Smitasirib Y, D’Souzac P, Neal-Kababickd J, Schauss AG: An Initial Evaluation of the Safety, Efficacy and Purity of VigRX, a Herbal Combination Formula, for the Enhancement of Male Sexual Health. The Open Natural Products Journal 2010, 3:10–19.
Chitaley K, Webb RC, Mills TM: The ups and downs of Rho-kinase and penile erection: upstream regulators and downstream substrates of rhokinase and their potential role in the erectile response. Int J Impot Res 2003, 15:105–109.
Chitaley K, Webb RC, Mills TM: Rho-kinase as a potential target for the treatment of erectile dysfunction. Drug News Perspect 2001, 14(10):601–606
Rosen R, Riley A, Wagner G, Osterloh I, Kirkpatrick J, Mishra A: The international index of erectile function (IIEF): a multidimensional scalefor assessment of erectile dysfunction. Urology 1997, 49:822–830.
Barnes PM, Powell-Griner E, McFann K, Nahin RL: Complementary and alternative medicine use among adults: United States, 2002. Advance data from vital and health statistics; no 343. Hyattsville, Maryland: National Center for Health Statistics; 2004
Thurairaja R, Barrass B, Persad R: Internet websites selling herbal treatments for erectile dysfunction. Int J Impot Res 2005, 17(2):196–200
Marwick C: Survey says patients expect little physician help on sex. JAMA 1999, 281(23):2173–2174.
Vickers A, Zollman C, Lee R: Herbal medicine. West J Med 2001, 175(2):125–128
de Andrade E, de Mesquita AA, Claro Jde A, de Andrade PM, Ortiz V, Paranhos M, Srougi M: Study of the efficacy of Korean Red Ginseng in the
Hong B, Ji YH, Hong JH, Nam KY, Ahn TY: A double-blind crossover study evaluating the efficacy of korean red ginseng in patients with erectile
Gauthaman K, Ganesan AP: The hormonal effects of Tribulus terrestris and its role in the management of male erectile dysfunction–an evaluation using primates, rabbit and rat. Phytomedicine 2008, 15(1–2):44–54
Gauthaman K, Adaikan PG, Prasad RN: Aphrodisiac properties of Tribulus Terrestris extract (Protodioscin) in normal and castrated rats. Life Sci 2002, 71(12):1385–1396
Gauthaman K, Ganesan AP, Prasad RN: Sexual effects of puncturevine (Tribulus terrestris) extract (protodioscin): an evaluation using a rat model. J Altern Complement Med 2003, 9(2):257–265.
Adimoelja A, Ganeshan AP: Protodioscin from herbal plant Tribulus terrestris L improves the male sexual functions, probably via DHEA. Int J Impot Res 1997, 9(supp 1):S1–S70.
Pytel Y, Vinarov A, Lopatkin N, Sivkov A, Gorilovsky L, Raynaud J: Long-term clinical and biological effects of the liposterolic extract of serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv Ther 2002, 19(6):297–306.
Arletti R, Benelli A, Cavazzuti E, Scarpetta G, Bertolini A: Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexualbehavior of male rats. Psychopharmacology (Berl) 1999, 143(1):15–19.
Estrada-Reyes R, Ortiz-López P, Gutiérrez-Ortíz J, Martínez-Mota L: Turnera diffusa Wild (Turneraceae) recovers sexual behavior in sexually exhausted males. J Ethnopharmacol 2009, 123(3):423–429
Paick JS, Lee JH: An experimental study of the effect of Ginkgo biloba extract on the human and rabbit corpus cavernosum tissue. J Urol 1996, 156:1876–1880
Liu WJ, Xin ZC, Xin H, Yuan YM, Tian L, Guo YL: Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. Asian J Androl 2005, 7(4):381–388
Tian L, Xin ZC, Liu WJ, Yang YM, Liu G, Chen L, Fu J, Wang LL: Effects of icariin on the erectile function and expression of nitrogen oxide synthase isoforms in corpus cavernosum of arterigenic erectile dysfunction rat model. Zhonghua Yi Xue Za Zhi 2004, 84(11):954–957.
Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC: Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998, 159(5):1541–1547.
Fransen HP, Pelgrom SM, Stewart-Knox B, de Kaste D, Verhagen H: Assessment of health claims, content, and safety of herbal supplements containing Ginkgo biloba. Food Nutr Res 2010, 54. doi:10.3402/fnr.v54i0.5221.
Santaella RM, Fraunfelder FW: Ocular adverse effects associated with systemic medications: recognition and management. Drugs 2007, 67(1):75–93.
Heaton J, Hackett GI, Savage D, Padley RJ: Patient choice is critical in managing erectile dysfunction. Eur Urol 2002, 3(Suppl. 1):33–37
Althof SE, Corty EW, Levine SB, Levine F, Burnett AL, McVary K, Stecher V, Seftel AD: EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999, 53(4):793–799.
Giannitsas K, Konstantinopoulos A, Patsialas C, Perimenis P: Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. Patient Preferences and Adherence 2008, 2:149–155
Montorsi P, Ravagnani PM, Galli S, Rotatori F, Briganti A, Salonia A, Dehò F, Montorsi F: Common grounds for erectile dysfunction and coronary artery disease. Curr Opinion Urol 2004, 14:361–365.
Gazzaruso C, Giordanetti S, De Amici E, Bertone G, Falcone C, Geroldi D, Fratino P, Solerte SB, Garzaniti A: Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004, 110(1):22–26.
Heruti R, Shochat T, Tekes-Manova D, Ashkenazi I, Justo D: Prevalence of erectile dysfunction among young adults: results of a large-scale survey. J Sex Med 2004, 1(3):284–291.
Moore TM, Strauss JL, Herman S, Donatucci CF: Erectile Dysfunction in Early, Middle, and Late Adulthood: Symptom Patterns and Psychosocial Correlates. J Sex Marital Ther 2003, 29(5):381–399.
Gott M, Hinchliff S: Barriers to seeking treatment for sexual problems in primary care: a qualitative study with older people. Fam Pract 2003, 20(6):690–695.
Montorsi P, Montorsi F, Schulman CC: Is erectile dysfunction the ‘tip of the iceberg’ of a systemic vascular disorder? Eur Urol 2003, 44:352–354
Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A, Galli S, Ravagnani PM, Montorsi P: Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003, 44:360–365.
Sun P, Cameron A, Seftel A, Shabsigh R, Niederberger C, Guay A: Erectile dysfunction–an observable marker of diabetes mellitus? A large national epidemiological study. J Urol 2006, 176(3):1081–1085
Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A, Salonia A, Deho F, Rigatti P, Montorsi F, Fiorentini C: Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J 2006, 27:2632–2639
Lizza EF, Rosen RC: Definition and classification of erectile dysfunction: Report of the nomenclature committee of the International Society of Impotence Research. Int J Impot Res 1999, 11:141–143.
Moyad MA: Dietary supplements and other alternative medicines for erectile dysfunction. What do I tell my patients? Urol Clin North Am 2002, 29(1):11–22. vii.